Last Updated : February 7, 2023
Details
FilesGeneric Name:
tezepelumab
Project Status:
Complete
Therapeutic Area:
Asthma
Manufacturer:
AstraZeneca Canada Inc.
Brand Name:
Tezspire
Project Line:
Reimbursement Review
Project Number:
SR0731-000
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Tezepelumab is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma.
Submission Type:
Initial
Fee Schedule:
Schedule A
Tumour Type:
N/A
Indications:
Tezepelumab is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Key Milestones2 | |
|---|---|
| Call for patient/clinician input open | March 17, 2022 |
| Call for patient/clinician input closed | May 06, 2022 |
| Clarification: - Patient input submission received from Asthma Canada and the Lung Health Foundation/The Ontario Lung Association | |
| Submission received | April 14, 2022 |
| Submission accepted | April 29, 2022 |
| Review initiated | May 02, 2022 |
| Draft CADTH review report(s) provided to sponsor for comment | July 15, 2022 |
| Deadline for sponsors comments | July 26, 2022 |
| CADTH review report(s) and responses to comments provided to sponsor | September 16, 2022 |
| Expert committee meeting (initial) | September 28, 2022 |
| Draft recommendation issued to sponsor | October 12, 2022 |
| Draft recommendation posted for stakeholder feedback | October 20, 2022 |
| End of feedback period | November 03, 2022 |
| Final recommendation issued to sponsor and drug plans | November 16, 2022 |
| Final recommendation posted | December 02, 2022 |
| Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | November 30, 2022 |
| CADTH review report(s) posted | February 06, 2023 |
Files
Last Updated : February 7, 2023